Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT1050220005
JPRN-jRCT1050220005
Recruiting
未知

Ovarian tissue cryopreservation as fertility preservation after childhood cancer treatment followed by long-term observation after storage. - Ovarian cryopreservation for cancer children

Fujisaki Hiroyuki0 sites100 target enrollmentApril 22, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCancer in children and AYAChildhood cancer, CAYA

Overview

Phase
未知
Intervention
Not specified
Conditions
Cancer in children and AYA
Sponsor
Fujisaki Hiroyuki
Enrollment
100
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 22, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Fujisaki Hiroyuki

Eligibility Criteria

Inclusion Criteria

  • •1\. Diagnose as childhood cancer or disease requiring hematopoietic stem cell transplantation.
  • •2\. Without previous chemotherapy and radiotherapy, or with previous treatments which minimally affect ovarian function.
  • •3\. Cancer treatments which expected to cause ovarian dysfunction at a high rate are planned.
  • •4\. Expected to survive 5\-year after cancer treatment (Probability does not matter)
  • •5\. Not eligible for other fertility\-preserving treatments.
  • •6\. One side of the ovary is retained even after ovariectomy.
  • •7\. Delay in initiation of cancer treatment due to OTC does not affect cancer outcome.
  • •8\. Written informed consent has been obtained from the patients and/or their guardians.

Exclusion Criteria

  • •1\. Clear tumor infiltration or metastasis to the ovary.
  • •2\. Severe ovarian dysfunction at the time of ovarian tissue cryopreservation because of cancer treatments, etc.
  • •3\. No uterus due to tumor resection, etc., or severe uterus dysfunction will be expected due to cancer treatments.
  • •4\. Severe neurocognitive impairment is observed or will be expected after cancer treatments.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Ovarian tissue cryopreservation for fertility preservatioPremature ovarian insufficiency
JPRN-UMIN000043460Sapporo Medical University33
Recruiting
Not Applicable
Ovarian tissue cryopreservation for fertility-preservation of Children and young adults with cancerCancer patient
JPRN-UMIN000021746Graduate school of medicine, Kyoto University Department of obstetrics and gynecology30
Recruiting
Phase 2
Fertility Preservation In Young Female Cancer SurvivorsHealth Condition 1: U072- COVID 19 virus not identified
CTRI/2023/02/049685Indian Council of Medical Research
Completed
Not Applicable
Preservation of fertility by cryopreservation of ovarian tissue and autologous transplantation of ovarian tissue in premenopausal women diagnosed with malignant tumorsBreast cancer, leukemia, malignant lymphoma (Hodgkin&#39s and Non-Hodgkin&#39s), other hematopoietic diseases (hypoplastic anemia, myelodysplastic syndrome, myeloma), sarcoma, systemic lupus erythematosus, rheumatic arthritis and other diseases requiring alkylating agents or radiation therapies.
JPRN-UMIN000029917Mie University Hospital5
Completed
Not Applicable
Preservation of fertility by cryopreservation of ovarian tissue and autologous transplantation of ovarian tissue in women under18 age diagnosed with malignant tumorsBreast cancer, leukemia, malignant lymphoma (Hodgkin&#39s and Non-Hodgkin&#39s), other hematopoietic diseases (hypoplastic anemia, myelodysplastic syndrome, myeloma), sarcoma, systemic lupus erythematosus, rheumatic arthritis and other diseases requiring alkylating agents or radiation therapies.
JPRN-UMIN000029918Mie University Hospital6